Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma

Oncologist

Volumn 5, Issue 2, 2000, Pages 144-151

  Agarwala, Sanjiv S ^a,b   Kirkwood, John M ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Alkylating; Antineoplastic agents; Central nervous system; Drug therapy; Imidazoles; Melanoma; Neoplasm metastasis; Pharmacokinetics

Indexed keywords

DACARBAZINE; TEMOZOLOMIDE;

ADULT; ADVANCED CANCER; AGED; ALKYLATION; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER GRADING; CENTRAL NERVOUS SYSTEM; CROSS LINKING; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; FEMALE; HUMAN; LIPOPHILICITY; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIORITY JOURNAL; REVIEW;

EID: 0034005995     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.5-2-144     Document Type: Review

References (46)

1. O'Reilly SM, Newlands ES, Glaser MG et al. Temozolomide: a new cytotoxic agent with promising activity against primary brain tumors. Eur J Cancer 1993;29:940-942.
2. Newlands ES, O'Reilly SM, Glaser MG et al. The Charing Cross Hospital experience with temozolomide in patients with gliomas. Eur J Cancer 1996;32A:2236-2241.
3. Bower M, Newlands ES, Bleehen NM et al. Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother Pharmacol 1997;40:484-488.
4. Yung WK, Prados MD, Yaya-Tur R et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J Clin Oncol 1999;17:2762-2771.
5. Newlands ES, Blackledge GR, Slack JA et al. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer 1992;65:287-291.
6. Bleehen NM, Newlands ES, Lee SM et al. Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol 1995;13:910-913.
7. 6-Methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma. Br J Cancer 1998;78:1199-1202.
8. Stevens MF, Hickman JA, Stone R et al. Antitumor imidazotetrazines. 1. Synthesis and chemistry of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3 H)-one, a novel broad-spectrum antitumor agent. J Med Chem 1984;27:196-201.
9. Newlands ES, Stevens MFG, Wedge SR et al. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 1997;23:35-61.
10. Patel M, McCully C, Godwin K et al. Plasma and cerebrospinal fluid pharmacokinetics of temozolomide. Proc Am Soc Clin Oncol 1995;14:461a.
11. Middleton M, Grob J, Aaronson N et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000;18:158-166.
12. 3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res 1987;47:5846-5852.
13. Reidenberg P, Statkevich P, Judson I et al. Effect of food on the oral bioavailability of temozolomide, a new chemotherapeutic agent. Proc Am Soc Clin Pharmacol Ther 1996;59:199a.
14. Brock CS, Newlands ES, Wedge SR et al. Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res 1998;58:4363-4367.
15. Data on File. Kenilworth, NJ: Schering-Plough Corporation, 1998.
16. Data on File. Study C193-H4. Kenilworth, NJ: Schering-Plough Corporation, 1998.
17. Nicholson HS, Ames MM, Krailo M et al. Phase I and pharmacokinetic study of temozolomide (TEM) in children and adolescents. A report from the Children's Cancer Group (CCG). Proc Am Soc Clin Oncol 1995;14:449a.
18. Dhodapkar M, Reid J, Ames MM et al. Phase I clinical trial and pharmacokinetics of temozolamide (NSC 362856). Proc Am Assoc Cancer Res 1994;35:245a.
19. Eckardt JR, Weiss GR, Burns HA et al. Phase I clinical trial and pharmacokinetic trial of SCH52365 (temozolomide) given orally daily × 5 days. Proc Am Soc Clin Oncol 1995;14:484a.
20. Estlin EJ, Lashford L, Ablett S et al. Phase I study of temozolomide in paediatric patients with advanced cancer. United Kingdom Children's Cancer Study Group. Br J Cancer 1998;78:652-661.
21. 5-alkyl-guanine-DNA alkyl transferase depletion (AT). Proc Am Soc Clin Oncol 1994;13:158a.
22. 6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide. Br J Cancer 1994;69:452-456.
23. 6-alkylguanine-DNA alkyltransferase with twice daily oral temozolomide (SCH 52365) in patients with advanced cancer. Proc Am Soc Clin Oncol 1996;15:178a.
24. 6-alkylguanine-DNA alkyltransferase analysis and response to temodal in newly diagnosed malignant glioma. J Clin Oncol 1998;16:3851-3857.
25. Levin V, Yung A, Prados M et al. Phase II study of Temodal® (temozolomide) at first relapse in anaplastic astrocytoma (AA) patients. Proc Am Soc Clin Oncol 1997;16:384a.
26. Huncharek M, Muscat J. Treatment of recurrent high grade astrocytoma; results of a systematic review of 1,415 patients. Anticancer Res 1998;18:1303-1312.
27. Yung WK, Mechtler L, Gleason MJ. Intravenous carboplatin for recurrent malignant glioma: a phase II study. J Clin Oncol 1991;9:860-864.
28. Jeremic B, Grujicic D, Jevremovic S et al. Carboplatin and etoposide chemotherapy regimen for recurrent malignant glioma: a phase II study. J Clin Oncol 1992;10:1074-1077.
29. Buckner J, Brown L, Cascino T et al. Phase II evaluation of infusional etoposide and cisplatin in patients with recurrent astrocytoma. J Neurooncol 1990;9:249-254.
30. Fulton D, Ursasun R, Forsyth P. Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma. J Neurooncol 1996;27:149-155.
31. Friedman HS, Petros WP, Friedman AH et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 1999;17:1516-1525.
32. Yung A, Levin VA, Albright R et al. Randomized trial of Temodal (TEM) vs. procarbazine (PCB) in glioblastoma multiforme (GBM) at first relapse. Proc Am Soc Clin Oncol 1999;18:139a.
33. Balch CM, Reintgen DS, Kirkwood JM et al. Cutaneous melanoma. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, 5th Ed. Philadelphia: Lippincott-Raven, 1997:1947-1994.
34. Chapman PB, Einhorn LH, Meyers ML et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999;17:2745-2761.
35. Atkins MB, Lotze MT, Dutcher JP et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17:2105-2116.
36. Legha S, Ring S, Eton O et al. Durable complete responses (CR's) in metastatic melanoma treated with biochemotherapy using cisplatin + vinblastine + DTIC (CVD) and IL-2 + interferon-alpha (IFN-α). Proc Am Soc Clin Oncol 1995;14:412a.
37. Legha SS, Ring S, Bedikian A et al. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha. Ann Oncol 1996;7:827-835.
38. Richards JM, Gale D, Mehta N et al. Combination of chemotherapy with interleukin-2 and interferon alfa for the treatment of metastatic melanoma. J Clin Oncol 1999;17:651-657.
39. Khayat D, Borel C, Tourani JM et al. Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma. J Clin Oncol 1993;11:2173-2180.
40. Rosenberg SA, Yang JC, Schwartzentruber DJ et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol 1999;17:968-975.
41. Keilholz U, Goey SH, Punt CJ et al. Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. J Clin Oncol 1997;15:2579-2588.
42. Data on file. 195-018. Kenilworth, NJ: Schering-Plough Corporation, 1998.
43. Agarwala S, Reyderman L, Statkevich P et al. Pharmacokinetic study of temozolomide penetration into CSF in a patient with dural melanoma. Ann Oncol 1998;9(suppl 4):659a.
44. Summers Y, Middleton M, Calvert H et al. Effect of temozolomide (TMZ) on central nervous system (CNS) relapse in patients with advanced melanoma. Proc Am Soc Clin Oncol 1999;18:531a.
45. Kirkwood JM, Agarwala SS, Diaz B et al. Phase I study of temozolomide in combination with interferon alfa-2b in metastatic malignant melanoma. Proc Am Soc Clin Oncol 1997;16:491a.
46. Britten CD, Rowinsky EK, Baker SD et al. A phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies. Clin Cancer Res 1999;5:1629-1637.